Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs

European Journal of Cancer

Volumn 39, Issue 10, 2003, Pages 1348-1354

  Ciardiello, F ^a   Tortora, Giampaolo ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

EGFR targeted therapy; EGFR TKI; Epidermal growth factor receptor (EGFR); Gefitinib ('Iressa', ZD1839); Signalling pathways

Indexed keywords

CETUXIMAB; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; G PROTEIN COUPLED RECEPTOR; GEFITINIB; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; BREAST CANCER; CANCER CONTROL; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELL STRAIN 3T3; CELL SURVIVAL; CLINICAL TRIAL; DNA DETERMINATION; ENZYME IMMUNOASSAY; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVIEW; RNA DEGRADATION; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

EID: 0038461104     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00235-1     Document Type: Review

References (50)

1. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs. 60(Suppl. 1):2000;25-32.
2. Ciardiello F., Tortora G. A novel approach in the treatment of cancer. targeting the epidermal growth factor receptor Clin. Cancer Res. 7:2001;2958-2970.
3. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:1995;183-232.
4. Klijn J.G., Berns P.M., Schmitz P.I., Foekens J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer. a review on 5232 patients Endocr. Rev. 13:1992;3-17.
5. Brabender J., Danenberg K.D., Metzger R.et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res. 7:2001;1850-1855.
6. Sartor C.I. Biological modifiers as potential radiosensitizers. targeting the epidermal growth factor receptor family Semin. Oncol. 27:2000;15-20.
7. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 82:1999;241-250.
8. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2:2001;127-137.
9. Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann. Oncol. 11(Suppl. 3):2000;187-190.
10. Baselga J., Averbuch S.D. ZD1839 ('Iressa') as an anticancer agent. Drugs. 60(Suppl. 1):2000;33-40.
11. Ranson M., Hammond L., Ferry D.et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors. results of a phase I trial J. Clin. Oncol. 20:2002;2240-2250.
12. Hidalgo M., Siu L.L., Nemunaitis J.et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19:2001;3267-3279.
13. Nicholson R.I., Gee J.M.W., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer. 37(Suppl. 4):2001;S9-15.
14. Robertson K.W., Reeves J.R., Lannigan A.K., Going J.J., Cooke T.G., Stanton P.D. Radioimmunohistochemistry of epidermal growth factor receptor in breast cancer. Arch. Pathol. Lab. Med. 126:2002;177-181.
15. Albanell J., Codony-Servat J., Rojo F.et al. Activated extracellular signal-regulated kinases. association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments Cancer Res. 61:2001;6500-6510.
16. Albanell J., Rojo F., Averbuch S.et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients. histopathologic and molecular consequences of receptor inhibition J. Clin. Oncol. 20:2002;110-124.
17. Volm M., Rittgen W., Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br. J. Cancer. 77:1998;663-669.
18. Aziz S.A., Pervez S., Khan S., Kayani N., Rahbar M.H. Epidermal growth factor receptor (EGFR) as a prognostic marker. an immunohistochemical study on 315 consecutive breast carcinoma patients J. Pak. Med. Assoc. 52:2002;104-110.
19. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in patients with breast cancer. Breast Cancer Res. Treat. 1029:2002;71. 67-75.
20. Magne N., Pivot X., Bensadoun R.-J.et al. The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur. J. Cancer. 37:2001;2169-2177.
21. Huang H.-J.S., Nagane M., Klingbeil C.K.et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phophorylation and unattenuated signaling. J. Biol. Chem. 272:1997;2927-2935.
22. Moscatello D.K., Holgado-Madruga M., Emlet D.R., Montgomery R.B., Wong A.J. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem. 273:1998;200-206.
23. Learn C.A., Archer G.E., Heimberger A.H.et al. Oral administration of the specific epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) is efficacious against EGFR-overexpressing intracranial tumors. Proc. Am. Assoc. Cancer Res. 43:2002;. (abstr).
24. Normanno N., Ciardiello F. EGF-related peptides in the pathophysiology of the mammary gland. J. Mammary Gland Biol. Neoplasia. 2:1997;143-151.
25. Umekita Y., Ohi Y., Sagara Y., Yoshida H. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int. J. Cancer. 89:2000;484-487.
26. Tateishi M., Ishida T., Mitsudomi T., Kaneko S., Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res. 50:1990;7077-7080.
27. Grandis J.R., Melhem M.F., Gooding W.E.et al. Levels of TGFα and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 90:1998;799-801.
28. Prenzel N., Zwick E., Leserer M., Ullrich A. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res. 2:2000;184-190.
29. Carpenter G. Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways. J. Cell Biol. 146:1999;697-702.
30. Bates S.E., Davidson N.E., Valverius E.M.et al. Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer. its regulation by estrogen and its possible functional significance Mol. Endocrinol. 2:1988;543-555.
31. Moasser M.M., Basso A., Averbuch S.D., Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61:2001;7184-7188.
32. Campiglio M., Normanno N., Olgiati C.et al. Blockage of the EGF-receptor by ZD1839 resulted in growth inhibition of human breast cancer cell lines with up-regulation of the activated EGFR and/or HER2. Proc. Am. Assoc. Cancer Res. 43:2002;603. (abstr).
33. Meye A., Fiedler U., Kunert K., Melchior A., Wirth M.P. Growth inhibitory effects of ZD1839 ('Iressa') on human bladder cancer cell lines. Proc. Am. Assoc. Cancer Res. 42:2001;805. (abstr).
34. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6:2000;4885-4892.
35. Budillon A., Guarrasi R., Di Gennaro E.et al. ZD1839 ('Iressa'), an EGFR tyrosine kinase inhibitor, potentiates non-Mhc restricted cytotoxicity in human cancer cell lines. Proc. Am. Assoc. Cancer Res. 42:2001;. (abstr).
36. Ciardiello F., Caputo R., Bianco R.et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6:2000;2053-2063.
37. Moulder S.L., Yakes F.M., Muthuswamy S.K., Bianco R., Simpson J.F., Arteaga C.L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61:2001;8887-8895.
38. Anido J., Albanell J., Rojo F., Arribas J., Averbuch S., Baselga J. ZD1839 ('Iressa'), a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2 overexpressing breast cancer cells. Proc. Am. Assoc. Cancer Res. 43:2002;783. (abstr).
39. Normanno N., Campiglio M., De Luca A.et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13:2002;65-72.
40. Herbst R.S., Maddox A.M., Rothenberg M.L.et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors. results of a phase I trial J. Clin. Oncol. 20:2002;3815-3825.
41. Baselga J., Rischin D., Ranson M.et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20:2002;4292-4302.
42. Perez-Soler R., Chachoua A., Huberman M.et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;310a. (abstr).
43. Baselga J., Pfister D., Cooper M.R.et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18:2000;904-914.
44. Stoehlmacher J., Brabender J., Shirota Y.et al. Association between mRNA expression level of epidermal growth factor receptor (EGFR), immunohistochemistry (IHC) and response to the EGFR-inhibitor C225 in advanced colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. 20:2001;149a. (abstr).
45. Rojo F., Albanell J., Anido J.et al. Dose dependent pharmacodynamic effects of ZD1839 ('Iressa') correlate with tumor growth inhibition in BT-474 breast cancer xenografts. Proc. Am. Assoc. Cancer Res. 43:2002;. (abstr).
46. Viloria-Petit A., Crombet T., Jothy S.et al. Aquired resistance to the antitumor activity of epidermal growth factor receptor-blocking antibodies in vivo. a role for altered tumor angiogenesis Cancer Res. 61:2001;5090-5101.
47. Chakravarti A., Loeffler J.S., Dyson N.I. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62:2002;200-207.
48. Ciardiello F., Damiano V., Bianco R.et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. Natl. Cancer Inst. 88:1996;1770-1776.
49. Ciardiello F., Caputo R., Bianco R.et al. Cooperative inhibition of renal cancer growth by anti-epideraml growth factor receptor antibody and protein kinase A antisense oligonucleotide. J. Natl. Cancer Inst. 90:1998;1087-1094.
50. Ciardiello F., Bianco R., Damiano V.et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 6:2000;3739-3747.